NEW YORK (GenomeWeb) – Swiss genomic data management firm BC Platforms said that it has struck a deal to incorporate Sentieon's next-generation sequencing data-processing software into its integrated genomics and clinical data products.
Sentieon offers a suite of bioinformatics secondary analysis tools for genomic data, including DNAseq and DNAscope for germline variant detection, and TNseq and TNscope for tumor-normal somatic variant detection. Under the terms of the deal, all of Sentieon's tools will be incorporated into BC Platform's system for the integration, secure analysis, and interpretation of molecular and clinical information. Additional terms were not disclosed.
"We are committed to working with our partners to advance the use of genomics and clinical data in order to enable precision medicine solutions on a population scale," BC Platforms CEO Tero Silvola said in a statement. "This partnership will provide our customers access to an end-to-end solution and the confidence to scale to any size in their quest to deliver on the promise of precision medicine for their patients."
Earlier this year, Qiagen signed a deal to integrate DNAseq and TNseq into its CLC Genomics Workbench for biomedical research and the Qiagen Clinical Insight platform for lab testing.